trial

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced…

16 hours ago

Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer

November 26, 2024 03:00 ET | Source: Anocca AB Application to the European Medicines Agency (EMA) covers ANOC-001 as the…

1 week ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…

2 weeks ago

Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial

First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction verification at the point of exchange - a…

2 weeks ago

Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial

First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction verification at the point of exchange - a…

2 weeks ago

Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial

First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction verification at the point of exchange - a…

2 weeks ago

Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial

First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction verification at the point of exchange - a…

2 weeks ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq:…

2 weeks ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

3 weeks ago